

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Details : Zevalin (Ibritumomab Tiuxetan) is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Follicular.
Product Name : Zevalin
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 10, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Details : Ibritumomab Tiuxetan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 24, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zevalin (Ibritumomab Tiuxetan) is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Zevalin
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 13, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
